Tufted hair folliculitis in a woman treated with trastuzumab
- 15 October 2010
- journal article
- case report
- Published by Springer Nature in Targeted Oncology
- Vol. 5 (4) , 295-296
Abstract
Chemotherapeutic agents targeting the human epidermal receptor (HER) family are being used with increasing frequency for a variety of solid tumors. Cutaneous side effects are commonly reported with HER inhibitors, especially those agents that inhibit epidermal growth factor receptor (EGFR) or HER1. However, inhibitors of HER2 are not associated with specific skin toxicity. We present a case of tufted hair folliculitis, an inflammatory scalp condition causing scaling and pruritus, in a woman being treated with trastuzumab, a selective HER2 inhibitor. This finding has not previously been reported as a side effect of trastuzumab therapy.Keywords
This publication has 5 references indexed in Scilit:
- Skin reactions to the new biologic anticancer drugsCurrent Opinion in Supportive & Palliative Care, 2009
- Tufted hair folliculitis in a woman treated with lapatinib for breast cancerClinical and Experimental Dermatology, 2008
- Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapiesBritish Journal of Cancer, 2005
- Human EGF Receptor (HER) Family and Heregulin Members Are Differentially Expressed in Epidermal Keratinocytes and Modulate DifferentiationExperimental Cell Research, 2001
- Tufted folliculitis of the scalp: a distinctive clinicohistological variant of folliculitis decalvansBritish Journal of Dermatology, 1998